Browse
Submit Data
Databases
API
Help

Dataset Information

17 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer

ABSTRACT: * Open-label, single-arm, phase II study of bevacizumab (AvastinTM) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer. * Primary objective: PFS, To assess overall resectability in patients with metastatic colorectal cancer, postoperative morbidity and outcomes after resection. * Secondary objectives: To assess response rates according to RECIST criteria, failure free survival (TTF) and overall survival (OS), Quality of life according to 15D questionnaire, To radiologically assess tumour density and morphology, and assess alternative radiologic response evaluation in comparison with RECIST response criteria, Biomarker evaluation to measure plasma biomarkers, tumour blocks and DNA polymorphisms that may predict drug effects, safety, resectability and clinical behaviour of the tumour

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2120245 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in Finland

Project description:* A population-based prospective study to evaluate clinical behaviour, resectability and survival in 1st line metastatic colorectal cancer (CRC) patients in Finland * Primary objective: To assess clinical behaviour of metastatic colorectal cancer and overall resectability, postoperative morbidity and outcomes after resection * Secondary objectives: To assess treatments for mCRC; To assess efficacy of chemotherapy and targeted drugs with overall response rates (ORR), failure free survival (FFS), progression free survival (PFS), and overall survival (OS); To radiologically assess tumour density and morphology, and assess alternative radiologic response evaluation in comparison with RECIST response criteria; To evaluate whole blood, plasma, serum and tumour block biomarkers and DNA polymorphisms that may predict drug effects, resectability and clinical behaviour of the tumour

| 2120247 | ecrin-mdr-crc

Ensayo clínico para evaluar la respuesta después de cirugía de metastásis hepáticas en cáncer colorrectal en tratamiento con bevacizumab y XELOX.

Project description:Primary objectives: Correlation between global objectives response according RECIST v1.1 criteria evaluated by conventional images tecniques with morfologic response by TAC and pathologic response after hepatic metastatic resectability. Primary endpoints: Objectives response rate according RECIST v1.1 criteria. Morfologic response rate by TCMD. Pathologic response rate after hepatic metastatic resectability.

| 2529162 | ecrin-mdr-crc

Durvalumab (MEDI4736) with or without tremelimumab in MSS and MSI colorectal and endometrial tumors

Project description:Primary objectives: To assess the antitumor activity of Durvalumab or Tremelimumab 300 mg single dose followed by Durvalumab in patients with microsatellite instable (MSI) colorectal cancer (CRC) or endometrial cancer (EC) and Tremelimumab 300 mg single dose followed by Durvalumab in refractory microsatellite stable (MSS) CRC and EC as defined by objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Primary endpoints: Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, and iRECIST if applicable, in patients with advanced, immune naïve MSS CRC, MSS EC, MSI CRC and MSI EC.

| 2735605 | ecrin-mdr-crc

Pembrolizumab for locally advanced, irresectable, non-metastatic dMMR colorectal cancers. The PUMA study.

Project description:Primary objectives: To determine the objective response rate (ORR) according to RECIST 1.1 criteria in order to assess the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancers Primary endpoints: Efficacy of pembrolizumab will be measured by the objective response rate (ORR) according to RECIST 1.1 criteria. The ORR (%) is defined as the proportion of patients with complete response (CR) or partial response (PR) according to RECIST 1.1 as the best observed response to pembrolizumab treatment. All subjects who were treated with at least one cycle of pembrolizumab and underwent subsequent evaluation of their disease will be considered evaluable for response.

| 2756173 | ecrin-mdr-crc

Examination of microRNA expression in pre- and post-treatment plasma samples of 3 patients

Project description:Drug resistance often tempers the clinical benefit of chemotherapy in human malignant tumors. The potential chemosensitization of low-dose decitabine has been evident both preclinically and in previous phase I trials. Emerging data showed that miRNAs play an important role as a prognostic factor for cancer survival. Given that the biopsy tumor tissue was often not available, especially for patients with relapsed or refractory cancer, plasma RNA provided a valuable source for biomarker development. In order to establish predictive biomarker signature for the clinical efficacy of the decitabine-primed chemotherapy, we evaluated the expression of plasma miRNAs via high throughput microRNA sequencing. We performed miRNA-seq on a training set of 2 partial response (PR) patients and 1 progressive disease (PD) patients, and revealed preliminary data that plasma miRNA expression signature may serve as putative predictive markers of the low-dose decitabine primed chemotherapy. The clinical responses were assessed in a blinded manner according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

2016-12-15 | GSE91089 | GEO

High-through put translational in vivo and ex vivo techniques for glioma molecular characterization and accurate classification, prognosis and treatment selection subset data from etumour consorteum Kal1

Project description:Tumour expression profiling was performed on resected brain tumour tissue following its histological categorisation. Classification of tumour type was carried out according to WHO criteria by a panel of independent pathologists across the etumour consorteum. This gave a high quality diagnostic evaluation, enabling stratification of patients by tumour type and grade. Sample quality was further assessed throughout sample processing allowing the use of minimum quality standards to be applied to all samples prior to profiling. This approach yielded high quality data that combined with diagnostic stratification enabled profiling by tumour type and grade, allowing the identification and investigation of gene signatures associated with these categories.

2013-10-01 | E-MTAB-1852 | biostudies-arrayexpress

The NEWEST trial

Project description:The NEWEST (Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumours) trial compared the clinical and biological activity of fulvestrant 500 mg vs 250 mg in the neoadjuvant setting. In this multi-centre phase II study, post-menopausal women with operable, locally advanced (T2, 3, 4b; N0-3; M0) ER-positive breast tumours were randomised to receive neoadjuvant treatment with either dose of fulvestrant for 16 weeks before surgery. Tumour core biopsies were obtained at baseline, 4 weeks and at surgery for assessment of changes in biomarker expression. Tumour volumes were measured by 3-D ultrasound at the same timepoints. In this trial, the percentage of patients who showed a reduction in tumour volume or stabilisation of disease (using RECIST criteria) after treatment with fulvestrant 500 mg was 36% (26 out of 69 patients). Therefore, within a population of endocrine-therapy naive patients whose tumours were confirmed as being ER-positive at the time of study entry, there is a subgroup who gained particular clinical benefit from fulvestrant treatment. These clinical response data together with the availability of biological response information and frozen tumour tissue from participants makes the NEWEST trial an attractive setting in which to investigate the potential of new markers of response to fulvestrant. 42 samples

2014-01-08 | E-GEOD-48905 | biostudies-arrayexpress

Monitoring of treatment with bevacizumab in patients with metastatic colorectal cancer

Project description:Study hypothesis: Observational study, recording safety according to the National Cancer Institute Common Toxicity Criteria (NCI CTC), version 3.0 and evaluating efficacy in standard clinical practice. Primary outcome(s): 1. Safety of treatment with bevacizumab 2. Response rate: Response Evaluation Criteria in Solid Tumors (RECIST) 3. Rate of radical surgical resection (R0 resection)

| 2420410 | ecrin-mdr-crc

CAPRI 2 GOIM study: investigate the efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line.

Project description:Primary objectives: Response Rate (RR) per each line of therapy: assessed according to RECIST criteria 1.1 Primary endpoints: Response Rate (RR) per each line of therapy assessed according to RECIST criteria 1.1

| 2540493 | ecrin-mdr-crc

A Study of Atezolizumab in Advanced Solid Tumors

Project description:The primary efficacy objective for this study is to evaluate non-progression rate (NPR) at 18 weeks in participants with advanced solid tumors treated with atezolizumab, defined as the percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1, or according to disease-specific criteria for prostate cancer and malignant pleural mesothelioma.

| 2191128 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data